seizure
The company’s Seer Home device allows for potential epilepsy diagnosis through at-home data collection.
The company will use the funding to support the commercial expansion of its product.
The company's REMI product is currently FDA cleared for in-hospital use, but Epitel plans to expand into ambulatory and in-home care.
The nearly 14-year-old company hopes to raise $75 million to support its implanted, closed-loop seizure prevention system.